NEW YORK – As part of an academic-industry partnership with Thermo Fisher Scientific, investigators and clinicians at the University of Pittsburgh Medical Center are currently pushing forward with an effort to definitively demonstrate both utility and health economic value for preemptive pharmacogenomic testing — an area of genomics that has been greeted with much enthusiasm over the years, but which has also faced significant hurdles.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.